Scarica l'app Stockscreener
1.27
3.05%
-0.04
Dopo l'orario di chiusura:
1.32
0.05
+3.94%
Precedente Chiudi:
$1.31
Aprire:
$1.2
Volume 24 ore:
1.93M
Relative Volume:
0.70
Capitalizzazione di mercato:
$251.85M
Reddito:
$314.00K
Utile/perdita netta:
$-40.23M
Rapporto P/E:
-4.5357
EPS:
-0.28
Flusso di cassa netto:
$-84.71M
1 W Prestazione:
-6.62%
1M Prestazione:
-15.89%
6M Prestazione:
+13.39%
1 anno Prestazione:
-48.16%
Intervallo 1D:
$1.16
$1.32
Intervallo di 1 settimana:
$1.16
$1.48
Portata 52W:
$1.03
$2.64
Atai Life Sciences N V Stock (ATAI) Company Profile
Nome
Atai Life Sciences N V
Settore
Industria
Telefono
49 89 2153 9035
Indirizzo
WALLSTRASSE 16, BERLIN
Confronta ATAI con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ATAI
Atai Life Sciences N V
|
1.27 | 251.85M | 314.00K | -40.23M | -84.71M | -0.28 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.56 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.78 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
550.00 | 33.54B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
232.95 | 30.15B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
220.54 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Atai Life Sciences N V Stock (ATAI) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-11-18 | Reiterato | H.C. Wainwright | Buy |
| 2024-04-03 | Aggiornamento | Maxim Group | Hold → Buy |
| 2022-11-01 | Iniziato | Loop Capital | Buy |
| 2021-11-30 | Iniziato | Maxim Group | Buy |
| 2021-11-11 | Iniziato | ROTH Capital | Buy |
| 2021-10-18 | Iniziato | H.C. Wainwright | Buy |
| 2021-09-01 | Iniziato | Jefferies | Buy |
| 2021-07-13 | Iniziato | Berenberg | Buy |
| 2021-07-13 | Iniziato | Canaccord Genuity | Buy |
| 2021-07-13 | Iniziato | Cantor Fitzgerald | Buy |
| 2021-07-13 | Iniziato | Citigroup | Buy |
| 2021-07-13 | Iniziato | Cowen | Outperform |
| 2021-07-13 | Iniziato | Credit Suisse | Outperform |
| 2021-07-13 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2021-07-08 | Iniziato | Aegis Capital | Buy |
Mostra tutto
Atai Life Sciences N V Borsa (ATAI) Ultime notizie
Berenberg starts atai Life Sciences coverage with Positive rating - Investing.com Australia
Berenberg starts atai Life Sciences coverage with Positive rating By Investing.com - Investing.com South Africa
How Are Things Looking For ATAI Life Sciences N.V (NASDAQ: ATAI) For The Short Term? - stocksregister.com
Atai Life Sciences CEO Rao Srinivas sells $101,814 in common shares - Investing.com Australia
Atai Life Sciences CEO Rao Srinivas sells $101,814 in common shares By Investing.com - Investing.com South Africa
Atai Life Sciences chief scientific officer sells $17,767 in shares By Investing.com - Investing.com South Africa
Atai life sciences CMO Craig James sells $15,610 in shares By Investing.com - Investing.com South Africa
Atai Life Sciences chief business officer sells $65,560 in stock By Investing.com - Investing.com South Africa
Atai Life Sciences chief business officer sells $65,560 in stock - Investing.com India
Atai Life Sciences chief scientific officer sells $17,767 in shares - Investing.com India
Atai Life Sciences CFO sells shares worth $45,285 - Investing.com India
Atai life sciences CMO Craig James sells $15,610 in shares - Investing.com India
Atai Life Sciences director Angermayer buys $2.52 million in shares By Investing.com - Investing.com UK
Atai Life Sciences director Angermayer buys $2.52 million in shares - Investing.com
Psychedelic: atai Life Sciences, NRx report quarterly results - Yahoo Finance
Nasdaq-Listed Biotech Firm Atai Life Sciences to Launch Bitcoin Treasury Strategy - Cryptonews
ATAI Life Sciences invests $5M in Bitcoin as reserve asset By Investing.com - Investing.com Australia
atai Life Sciences Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights - The Manila Times
ATAI Life Sciences N.V. (ATAI) reports earnings - Quartz
Psychedelic: atai reports dosing of first patient in Phase 2 VLS-01 trial - TipRanks
atai Life Sciences Announces First Patient Dosed in Elumina, the Phase 2 Clinical Trial of VLS-01 for Treatment-Resistant Depression - Yahoo Finance
Is Atai Life Sciences N.V. (ATAI) Among Stocks With At Least $20 Million In Insider Spending Recently? - Insider Monkey
10 Stocks With At Least $20 Million In Insider Spending Recently - Insider Monkey
How is ATAI’s stock performing after recent trades? - US Post News
Atai Life Sciences N.V. (ATAI): Among the Best Psychedelic Stocks to Buy in 2025 - Insider Monkey
12 Best Psychedelic Stocks to Buy in 2025 - Insider Monkey
ATAI’s Market Quandary: Decoding the Ups and Downs of 2023 - The InvestChronicle
Atai: Following The Path That Spravato Laid And Moving Beyond It - Seeking Alpha
Comprehensive Market Analysis of Latest Published Different Types of Depression Reports | DelveInsight - GlobeNewswire Inc.
atai Life Sciences to Participate in the TD Cowen 45th Annual Health Care Conference - Yahoo Finance UK
Biotechs Highlight 6 Stocks Insiders Are Buying Now - 24/7 Wall St.
Atai Life Sciences Raises $63.3 Million After Closing Public Offering -February 20, 2025 at 10:10 am EST - Marketscreener.com
atai Life Sciences completes public offering, raising $63.25M - Proactive Investors UK
atai Life Sciences Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Common Shares - Yahoo Finance UK
Apeiron Investment Group purchases $22.8m in ATAI Life Sciences shares By Investing.com - Investing.com Australia
Drug developers struggle in 2024; Fibrogen, Acadia, Atai post gains - BioWorld Online
atai Life Sciences announces pricing of $55M public offering of shares - Proactive Investors UK
Trade Desk Posts Downbeat Revenue, Joins Aspen Aerogels, Fastly And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Benzinga
Atai Life Sciences Prices $55 Million Stock Offering -February 13, 2025 at 04:47 am EST - Marketscreener.com
ATAI Life Sciences Secures Massive $55M War Chest for Breakthrough Mental Health Treatments - StockTitan
atai Life Sciences Announces Pricing of Public Offering of Common Shares - Yahoo Finance
atai Life Sciences unveils $55M public offering to advance mental health treatments - Proactive Investors USA
atai Life Sciences Secures Major Funding: $55M Share Offering to Revolutionize Mental Health Treatment Pipeline - StockTitan
Atai CEO Rao optimistic about psychedelic therapies despite Lykos setback (ATAI:NASDAQ) - Seeking Alpha
Evaluating ATAI’s financial ratios for a profitable investment - US Post News
Get in on ATAI Life Sciences N.V’s (ATAI) buy-in window today! - SETE News
atai Life Sciences CEO discusses success of BPL-003 alcohol use disorder trialICYMI - Proactive Investors USA
Atai Life Sciences N V Azioni (ATAI) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):